The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies

Oncologist

Volumn 6, Issue SUPPL. 5, 2001, Pages 32-39

  Giles, F J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Leukemia; Lymphoma; SU5416; VEGF

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MATRIX METALLOPROTEINASE; PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR;

ACUTE LEUKEMIA; ANGIOGENESIS; BLOOD DISEASE; CHRONIC LEUKEMIA; CONFERENCE PAPER; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; HODGKIN DISEASE; HUMAN; METASTASIS; MITOGENESIS; MULTIPLE MYELOMA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0035168739     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_5-32     Document Type: Conference Paper

References (57)

1. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome
2. Multifaceted approach to the diagnosis and classification of acute leukemias
3. Prognostic factors in acute myelogenous leukemia
4. Multiple myeloma and other differentiated B-cell disorders
5. Secondary myelodysplastic syndromes and leukemias
6. World Health Organization classification of the acute leukemias and myelodysplasfic syndrome
7. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
8. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
9. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
10. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
11. Angiogenesis in acute myeloid leukemia
12. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis
13. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
14. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
15. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
16. Angiogenesis in myelodysplastic syndromes
17. Vascular endothelial growth factor
18. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3
19. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing
20. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
21. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants
22. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis
23. Vascular-specific growth factors and blood vessel formation
24. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
25. VEGF: An update on biological and therapeutic aspects
26. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia
27. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
28. Angiogenesis in multiple myeloma
29. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
30. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival
31. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
32. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
33. TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma
34. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single-institution study of 200 patients
35. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
36. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia
37. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia
38. A predictive model for aggressive non-Hodgkin's lymphoma
39. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
40. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies
41. Angiogenesis: Models and modulators
42. The role of αv integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
43. Target molecules for anti-angiogenic therapy: From basic research to clinical trials
44. Anti-angiogenic agents: Clinical trial design and therapies in development
45. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
46. Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen
47. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
48. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
49. Kit signal transduction
50. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117)
51. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells
52. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
53. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
54. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts
55. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
56. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
57. Clinical strategy for the development of angiogenesis inhibitors